Lapatinib ditosylate monohydrate
Key facts
| Active substance |
Lapatinib ditosilate monohydrate
|
| Therapeutic area |
Oncology
|
| Decision number |
P/36/2009
|
| PIP number |
Lapatinib ditosylate monohydrate
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Carcinoma of the head and neck (Covered by class waiver: oropharyngeal epithelial carcinoma, excluding nasopharyngeal carcinoma)
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Glaxo Group Limited
|
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|